Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of canakinumab in systemic juvenile idiopathic arthritis
2008-008008-42Phase 3
- Sponsor
- Novartis
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of canakinumab in systemic juvenile idiopathic arthritis (SJIA) and juvenile idiopathic arthritis (JIA), sponsored by Novartis. Primary endpoints: Long-term safety of canakinumab, Long-term tolerability of canakinumab and 1 more.
02
Drugs
canakinumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on 2008-008008-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008008-42.